Your browser doesn't support javascript.
loading
Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin.
Painter, Ronald E; Adam, Gregory C; Arocho, Marta; DiNunzio, Edward; Donald, Robert G K; Dorso, Karen; Genilloud, Olga; Gill, Charles; Goetz, Michael; Hairston, Nichelle N; Murgolo, Nicholas; Nare, Bakela; Olsen, David B; Powles, Maryann; Racine, Fred; Su, Jing; Vicente, Francisca; Wisniewski, Douglas; Xiao, Li; Hammond, Milton; Young, Katherine.
Afiliação
  • Painter RE; In vitro Pharmacology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Adam GC; Screening and Protein Sciences, Merck Research Laboratories, North Wales, PA 19454, USA.
  • Arocho M; Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • DiNunzio E; In vitro Pharmacology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Donald RG; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Dorso K; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Genilloud O; Centro de Investigación Básica (CIBE), Merck Sharp & Dhome de España, S.A., 28027 Madrid, Spain.
  • Gill C; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Goetz M; Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Hairston NN; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Murgolo N; Discovery Pharmacogenomics, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Nare B; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Olsen DB; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Powles M; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Racine F; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Su J; Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Vicente F; Centro de Investigación Básica (CIBE), Merck Sharp & Dhome de España, S.A., 28027 Madrid, Spain.
  • Wisniewski D; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Xiao L; Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Hammond M; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
  • Young K; Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA. Electronic address: katherine_young@merck.com.
Chem Biol ; 22(10): 1362-73, 2015 Oct 22.
Article em En | MEDLINE | ID: mdl-26456734
ABSTRACT
Resistance to existing classes of antibiotics drives the need for discovery of novel compounds with unique mechanisms of action. Nargenicin A1, a natural product with limited antibacterial spectrum, was rediscovered in a whole-cell antisense assay. Macromolecular labeling in both Staphylococcus aureus and an Escherichia coli tolC efflux mutant revealed selective inhibition of DNA replication not due to gyrase or topoisomerase IV inhibition. S. aureus nargenicin-resistant mutants were selected at a frequency of ∼1 × 10(-9), and whole-genome resequencing found a single base-pair change in the dnaE gene, a homolog of the E. coli holoenzyme α subunit. A DnaE single-enzyme assay was exquisitely sensitive to inhibition by nargenicin, and other in vitro characterization studies corroborated DnaE as the target. Medicinal chemistry efforts may expand the spectrum of this novel mechanism antibiotic.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Polimerase III / Descoberta de Drogas Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Polimerase III / Descoberta de Drogas Idioma: En Ano de publicação: 2015 Tipo de documento: Article